NYSE: ATRAptargroup Inc Stock
$148.56+1.35 (+0.92%)
Updated Mar 26, 2025
ATR Price
$148.56
Fair Value Price
N/A
Market Cap
$9.88B
52 Week Low
$135.96
52 Week High
$178.03
P/E
26.29x
P/B
4x
P/S
2.92x
PEG
5.31x
Dividend Yield
0.88%
Revenue
$3.58B
Earnings
$374.54M
Gross Margin
37.8%
Operating Margin
14.35%
Profit Margin
10.5%
Debt to Equity
0.79
Operating Cash Flow
$643M
Beta
0.73
Next Earnings
Apr 23, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ATR Overview
AptarGroup, Inc. manufactures consumer dispensing packaging and drug delivery devices. Its packaging solutions are offered in the beauty, personal care, and home care sectors. Its drug delivery devices include nasal pumps and metered dose inhaler valves. Other offerings include dispensing and non-dispensing closures, elastomeric flow control components, spray pumps, and aerosol valves. Aptar was incorporated in 1992 and is headquartered in Crystal Lake, IL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ATR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
ATR
Ranked#26 of 43
Ranked#26 of 43
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $49.41 | B | |
| $103.70 | B | |
| $6.04 | B |
Be the first to know about important ATR news, forecast changes, insider trades & much more!
ATR News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ATR scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATR ($148.56) is trading above its intrinsic value of $40.80, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ATR is good value based on its earnings relative to its share price (26.29x), compared to the US market average (31.65x)
P/E vs Market Valuation
ATR is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more ATR due diligence checks available for Premium users.
Valuation
ATR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
26.29x
Industry
41.69x
Market
31.65x
ATR is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ATR is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ATR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4x
Industry
3.78x
ATR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ATR price to earnings growth (PEG)
For valuing profitable companies with growth potential
ATR is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
ATR's financial health
Profit margin
Revenue
$848.1M
Net Income
$100.9M
Profit Margin
11.9%
ATR's Earnings (EBIT) of $514.03M... subscribe to Premium to read more.
Interest Coverage Financials
ATR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$4.4B
Liabilities
$1.9B
Debt to equity
0.79
ATR's short-term assets ($1.48B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATR's short-term assets ($1.48B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$178.2M
Investing
-$171.1M
Financing
-$87.7M
ATR's operating cash flow ($643.41M)... subscribe to Premium to read more.
Debt Coverage Financials
ATR vs Medical Stocks
Aptargroup Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.